Clinical Trials
47 trialsEfficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
People's Hospital of Quzhou
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Novartis
GPS
AstraZeneca
Keynote-593
Merck Sharp & Dohme LLC
TAIL
Hoffmann-La Roche
WAVE
AstraZeneca
IMPROVE-I
Radboud University Medical Center
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
Samsung Medical Center
Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC
West China Hospital
ROSIE
Radboud University Medical Center
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Pfizer
PCG
Genentech, Inc.
BUDDY
Chonnam National University Hospital
IMPROVE-III
Radboud University Medical Center
Osimertinib Study in Indian Patients
AstraZeneca
PKAPIR
Centre Georges Francois Leclerc
Study of Nivolumab for Advanced Cancers in India
Bristol-Myers Squibb
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Boehringer Ingelheim
Oncoxin® and Quality of Life in Cancer Patients
Catalysis SL
Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Boehringer Ingelheim
ABOUND 70+
Celgene
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
University of Kansas Medical Center
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
Fundacion Clinic per a la Recerca Biomédica
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Fox Chase Cancer Center
INFORM
AstraZeneca
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
Hoffmann-La Roche
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
Tianjin Medical University Cancer Institute and Hospital
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Hoffmann-La Roche
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
Hoffmann-La Roche
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Betta Pharmaceuticals Co., Ltd.
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Maestro Clinical, Inc.
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
Sun Yat-sen University
BLEST
Sun Yat-sen University
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Eli Lilly and Company
Modafinil for the Treatment of Fatigue in Lung Cancer V9.0
University of Oxford
SELINE
AstraZeneca
Pemetrexed Followed by Docetaxel or in Reverse Sequence
Taipei Veterans General Hospital, Taiwan
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Taipei Veterans General Hospital, Taiwan
Chemotherapy for Patients With Non-Small Cell Lung Cancer
Eli Lilly and Company
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
AstraZeneca
Non-small Cell Lung Cancer Registry
Novartis
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Amgen